Prosecution Insights
Last updated: April 19, 2026
Application No. 18/627,322

PATHOLOGICAL SLIDES AND RELATED SYSTEMS AND METHODS

Non-Final OA §101§103
Filed
Apr 04, 2024
Examiner
MUI, CHRISTINE T
Art Unit
1797
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Leavitt Medical Inc.
OA Round
3 (Non-Final)
78%
Grant Probability
Favorable
3-4
OA Rounds
2y 10m
To Grant
98%
With Interview

Examiner Intelligence

Grants 78% — above average
78%
Career Allow Rate
1060 granted / 1354 resolved
+13.3% vs TC avg
Strong +20% interview lift
Without
With
+19.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
68 currently pending
Career history
1422
Total Applications
across all art units

Statute-Specific Performance

§101
2.5%
-37.5% vs TC avg
§103
44.7%
+4.7% vs TC avg
§102
25.4%
-14.6% vs TC avg
§112
20.0%
-20.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1354 resolved cases

Office Action

§101 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 22 JANUARY 2026 has been entered. Status of Claims The claim set filed on 22 JANUARY 2026 is considered. In the claim set, Claims 1-6 are ‘Cancelled’; Claim 7, 10 is ‘Currently Amended’; Claims 8-9, 11, 12-15 are ‘Previously Presented’; Claims 16-18 are ‘New’. Current pending claims are Claims 7-18 and are considered on the merits below. Drawings The drawings are objected to as failing to comply with 37 CFR 1.84(p)(4) because reference character “408” in Figure 4. In Figure 4, the reference character “408” point to two different things. It appear the “408” on the right is correct as it points to a first region, but is unclear what the “408” on the left is referring to. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Objections Claim 16 is objected to because of the following informalities: In the last line, should “a pathology slide” be “the pathology slide”, since a pathology slide is already positively claimed? Appropriate correction is required. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. In addition to the 101 rejection by the previous Examiner, the current examiner has performed a 101 analysis as well of the pending claims. PNG media_image1.png 278 548 media_image1.png Greyscale PNG media_image2.png 210 536 media_image2.png Greyscale Claim 7 is rejected under 35 U.S.C. 101 because the claimed invention is directed to an abstract idea without significantly more. The independent claim, Claim 7 recites: a claim(s) recites a computer-implemented method for biopsy tissue sample processing performed by a processor of a pathology, computing system, the processor being is programmed to: receive, from a user via user input to a graphical user interface of the pathology computing system, a first identification of a pathology stain and of a first tissue sample to be stained with the pathology stain, the first tissue sample originating from a first patient; receive, from the user via user input to the graphical user interface of the pathology computing system, a second identification of the same pathology stain and of a second tissue sample to be stained with the same pathology stain, the second tissue sample originating from a second, different patient; cause instructions to be provided, through an electronic communication network to a laboratory computing system, for a first section of the first tissue sample to be positioned on a pathology slide in a first region of the pathology slide, wherein the first region is on a first side of a visibly perceptible separation mark on or in a substantially transparent substrate of the pathology slide; and cause instructions to be provided, through the electronic communication network to the laboratory computing system, for a second section of the second tissue sample to be positioned on the same pathology slide in a second region of the same pathology slide, wherein the second region is on a second, opposite side of the visibly perceptible separation mark. The limitations of ‘receive …a first identification from a pathology stain…’ and ‘receive … a second identification from a pathology stain…’ , as drafted is a process that, under its broadest reasonable interpretation, covers performance of the limitation in the mind but the recitation in the preamble of computer-implemented method. That is, other than recited a ‘computer implemented’, nothing in the claim elements precludes the step from practically being performed in the mind. Even the ‘cause instructions to be provided, through an electronic communication network…’ covers performance of the limitation in the mind but for the recitation of generic computer components. For example, but for the “the processor being programmed to” language, “programmed to” in the context of this claim encompasses the user thinking what tasks should be performed. If a claim limitation, under its broadest reasonable interpretation, covers performance of the limitation in the mind but for the recitation of generic computer components, then it falls within the “Mental Processes” grouping of abstract ideas. Accordingly, the claim recites an abstract idea. This judicial exception is not integrated into a practical application. In particular, in Claim 7, because the elements in all the claims do not impose any meaningful limits on practicing the abstract idea. The computer or processor in both steps is recited at a high-level of generality (i.e., as a generic processor performing a generic computer function of causing instructions based on the first and second identification) such that it amounts no more than mere instructions to apply the exception using a generic computer component. Accordingly, this additional element does not integrate the abstract idea into a practical application because it does not impose any meaningful limits on practicing the abstract idea. The claim is directed to an abstract idea.. This does not appear to have ‘significantly’ more; all steps in the method are WURC. The elements in Claim 7 (and its dependent claims directed to what the processor is programmed to do ) are all steps are WURC (well understood routine and conventional). The method is claimed at a high level of generality, there is no meaningful limitation claimed, such as a particular or unconventional machine or transformation of a particular article. Dependent Claim 15 does not impose any meaningful limits on practicing the abstract idea and only further define where the visibly perceptible separation mark is located. As discussed above with respect to integration of the abstract idea into a practical application, the additional element of using a computer or even a processor or a network to perform both the instruction steps amounts to no more than mere instructions to apply the exception using a generic computer component. Mere instructions to apply an exception using a generic computer component cannot provide an inventive concept. Dependent claims 8-14 and 16-18 further define abilities/capabilities or programmed functions which are at least obvious and/or anticipated by the prior art or are abilities that are well understood, routine and convention. The limitations in the above mentioned claims are do not impose any meaningful limits on practicing the abstract idea. Below is the 101 analysis. Step 1: The claim recites at least one step or act. Thus, the claim is to a method, which is one of the statutory categories of invention (Step 1: YES). Step 2A Prong One: The claim recites a judicial exception and identify the abstract idea/law of nature/natural phenomenon. The steps ‘receive …a first identification from a pathology stain…’ and ‘receive … a second identification from a pathology stain…’ ; it is an abstract idea; this can be done mentally or by the human eye. This can also be done with a look up table, would be considered an evaluation (mental step) and therefore an abstract idea. In addition, the limitations in the ‘cause instruction’ steps are insignificant and the limitation in Claim 9 of tracking information as well as Claim 11 to split the image obtained , Claims 12-14 describes how the processor obtains, processes or stores the images; is a judicial exception, (an abstract idea that falls within the mathematical concept and mental process groupings in the 2019 PEG, and a law of nature). This claim identifies the recited exception as an abstract idea. This claim attempts to process the information associated with information associated with the first and second digital images, Claim 18, but then nothing is done. This can be performed by a human using metal steps or basic critical thinking, which is an abstract idea (Step 2A: YES). Also consider MPEP 2106.040 (a)(2)(III). This judicial exception is not integrated into a practical application because the elements in all the claims do not impose any meaningful limits on practicing the abstract idea. The claim is directed to an abstract idea. Step 2A Prong Two: The claim as a whole integrates the recited judicial exception into a practical application of the exception; No. After Claim 7 and the ‘cause’ steps there does not appear to have any additional steps which are significantly more than the abstract idea. The other steps in dependent at least Claims 8 and 10-13 are anticipated by the previous Examiner. I will conduct a new search for all other claims and new claims. Step 2B: does the claim recite any elements which are significantly more than the abstract idea? This does not appear to have ‘significantly’ more; all steps in the method are WURC. The elements in Claim 7 (and its dependent claims directed to what the processor is programmed to do )are all steps are WURC (well understood routine and conventional). The method is claimed at a high level of generality, there is no meaningful limitation claimed, such as a particular or unconventional machine or transformation of a particular article. The claim is ineligible. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 7-18 are rejected under 35 U.S.C. 103 as being unpatentable over EHLKE, US Publication No. 2011/0060766 A1, and further in view of CHU, US Publication No. 2006/0216744 A1. Applicant’s invention is directed towards a method. Regarding Claim 7, the EHLKE reference discloses a computer-implemented method, Figure 1, 4 and 25, Claim 23, for biopsy tissue sample processing performed by a processor of a pathology, [0026], computing system, [0029, 0087], computer 410, Figure 4, the processor being is programmed to: receive, from a user via user input to a graphical user interface of the pathology computing system, [0017, 0027, 0059, 0092], user input is entered, a first identification of a pathology stain, [0117], Figure 7, and of a first tissue sample to be stained with the pathology stain, [0004, 0024, 0117], tissue sample are obtained, the first tissue sample originating from a first patient, [0004, 0024]; receive, from the user via user input to the graphical user interface of the pathology computing system, [0017, 0027, 0059, 0092], user input is entered, a second identification of the same pathology stain and of a second tissue sample to be stained with the same pathology stain, [0117, 0211], the second tissue sample originating from a second, different patient, [0004, 0024]; cause instructions to be provided, through an electronic communication network to a laboratory computing system, [0095], execution of program from a network, for a first section of the first tissue sample to be positioned on a pathology slide in a first region of the pathology slide, [0005, 0006], known in the art of pathology, slide trays have multiple slots with multiple samples, which include tissue, wherein the first region is on a first side of a visibly perceptible separation mark on or in a substantially transparent substrate of the pathology slide, [0005] slide are standard glass rectangles; and cause instructions to be provided, through the electronic communication network to the laboratory computing system, [0095], execution of program from a network, for a second section of the second tissue sample to be positioned on another pathology slide in a second region of the same pathology slide, wherein the second region is on a second, [0005, 0006]. The EHLKE discloses the claimed method, but is silent in regards to a second section of the second tissue sample to be positioned on the same pathology slide in a second region of the same pathology slide, wherein the second region is on a second, opposite side of the visibly perceptible separation mark. The CHU reference discloses a computer-implemented method, abstract, for biopsy tissue sample processing performed by a processor of a pathology, [0072, 0081-0088], Example 7, processing unit, cause instructions to be provided, through an electronic communication network to a laboratory computing system, [0081-0088], Example 7, processing unit, for a first section of the first tissue sample to be positioned on a pathology slide in a first region of the pathology slide, [0015], Figure 6A-E, tray 400 with at least well 410 for a first sample such as tissue, [0019, 0023], wherein the first region is on a first side of a visibly perceptible separation mark on or in a substantially transparent substrate of the pathology slide, Figure 6A-E, trough 420 is visible and is interpreted to be a mark or marks/color [0027]; and cause instructions to be provided, through the electronic communication network to the laboratory computing system, [0081-0088], Example 7, processing unit, for a second section of the second tissue sample to be positioned on the same pathology slide in a second region of the same pathology slide, [0015], Figure 6A-E, tray 400 with at least well 410 for a first sample such as tissue, [0019, 0023], wherein the second region is on a second, opposite side of the visibly perceptible separation mark, Figure 6A-E, another one of well 410 and trough 420 is visible and is interpreted to be a mark or marks/color [0027]. It would be obvious to one having ordinary skill in the art before the effective filing to modify the EHLKE so that a second section of the second tissue sample to be positioned on the same pathology slide in a second region of the same pathology slide, wherein the second region is on a second, opposite side of the visibly perceptible separation mark, which would allow one to recover the reaction fluid and to assay this fluid, prior to continuing the work-up of the tissue sample, to determine whether the PCR has worked properly or has been contaminated and allows more than one set of data to be view simultaneously, [0086, 0087]. Additional Disclosures Included by the combination includes : Claim 8: wherein the method of claim 7, wherein the processor is further programmed to transmit, through the electronic communication network to the laboratory computing system, an instruction to apply the pathology stain to the first section and to the second section, EHLKE [0095].; Claim 10: wherein the method of claim 7, wherein at least one of the processor of the pathology computing system or the processor of the laboratory computing system is programmed to cause an image sensor, communicatively coupled to at least one of the laboratory computing system or the pathology computing system, to take a digital image of the pathology slide, the digital image comprising the first section of the first tissue sample, positioned in the first region of the pathology slide, and the second section of the second tissue sample, positioned in the second region of the pathology slide, EHLKE Figure 3, [0011, 0012, 0018, 0019].; Claim 11: wherein the method of claim 10, wherein at least one of the processor of the pathology computing system, the processor of the laboratory computing system, or a processor of a server is further programmed to split the digital image into a first digital image including the first section and a second digital image including the second section, EHLKE [0019, 0024], Claim 28. ; Claim 12: wherein the method of claim 11, wherein at least one of the processor of the pathology computing system, the processor of the laboratory computing system, or the processor of the server is further programmed to cause a storage system, in communication with the pathology computing system, the laboratory computing system, and the server, to: associate, within the storage system, the first digital image with a first digital file corresponding to the first patient; and associate, within the storage system, the second digital image with a second digital file corresponding to the second, different patient, EHLKE Figure 4, memory, [0023, 0079, 0086, 0094, 0095]. ; Claim 13: wherein the method of claim 10, wherein the processor of the pathology computing system is further programmed to digitally analyze at least a portion of the digital image to identify at least one feature in the digital image, EHLKE [0009], Claim 23.; Claim 14: wherein the method of claim 10, wherein the processor of the pathology computing system is further programmed to present, via the graphical user interface of the pathology computing system, at least a portion of the digital image to the user for review, EHLKE [0115-0117], Figure 7 and 13-16A, 17B-19. ; Claim 15: wherein the method of claim 7, wherein the visibly perceptible separation mark is located on a bottom major surface of the pathology slide, EHLKE [0119]. ; Claim 16: wherein the method of claim 7, wherein the processor of the pathology computing system is programmed to receive at least one of the first identification or the second identification by decoding identification information from at least one of a printed slide label, a barcode, a two-dimensional scannable code, or an RFID chip located in a tracking region of a pathology slide, EHLKE [0119], Figure 15A-D, top of slide where it is labeled example : “1AHHEL1”.; Claim 17: wherein the method of claim 10, wherein at least one of the processor of the pathology computing system or the processor of the laboratory computing system is programmed to cause the image sensor to capture, in the digital image, a tracking region of the pathology slide that includes identification information, Claims 4-7, [0119, 0151, 0168, 0210].; and Claim 18: wherein the method of claim 12, wherein at least one of the processor of the pathology computing system, the processor of the laboratory computing system, or the processor of the server is programmed to associate the first digital image and the second digital image with respective patient digital files based at least in part on identification information obtained from a tracking region of the pathology slide, Claims 4-7, [0119, 0151, 0168, 0210]. Regarding Claim 9 , the combination above suggests the claimed invention, but is silent in regard to wherein at least one of the processor of the pathology computing system, a processor of the laboratory computing system, or a processor of a server is further programmed to transmit, through the electronic communication network to a printing device, instructions to print a label on the pathology slide with information, the information identifying at least one of: tracking information for the first tissue sample and for the second tissue sample; the pathology stain to be applied to the first section and to the second section; a date; the first tissue sample and the second tissue sample; or the first patient and the second, different patient. EHLKE shows in Figure 1 information is to be transmitted as well as displayed, Figure 4, displays 428/430. In addition, it is well known in the art that in physical pathology systems, slides are labeled near one end, [0119, 0124, 0151], in addition, slides are typically labeled as to sample identity, and may be associated with other slides for the same patient as well as with a patient file containing other information such as patient history information and test results, [0004]. It would be obvious to one having ordinary skill in the art before the effective filing date to have the processor actually instruct a printing device to have instructions to print a label on the pathology slide with information to identify sample and other sample/patient information, [0004]. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTINE T MUI whose telephone number is (571)270-3243. The examiner can normally be reached M-Th 5:30 -15:30 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, LYLE ALEXANDER can be reached at (571) 272-1254. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. CTM /CHRISTINE T MUI/Primary Examiner, Art Unit 1797
Read full office action

Prosecution Timeline

Apr 04, 2024
Application Filed
Mar 06, 2025
Non-Final Rejection — §101, §103
Jun 05, 2025
Applicant Interview (Telephonic)
Jun 12, 2025
Response Filed
Sep 19, 2025
Final Rejection — §101, §103
Dec 05, 2025
Applicant Interview (Telephonic)
Dec 06, 2025
Examiner Interview Summary
Dec 18, 2025
Applicant Interview (Telephonic)
Dec 21, 2025
Examiner Interview Summary
Jan 22, 2026
Request for Continued Examination
Jan 28, 2026
Response after Non-Final Action
Feb 19, 2026
Non-Final Rejection — §101, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12601727
Soil Analysis Compositions and Methods
2y 5m to grant Granted Apr 14, 2026
Patent 12589388
Multi-channel parallel pretreatment device
2y 5m to grant Granted Mar 31, 2026
Patent 12569846
MICROFLUIDIC REACTION VESSEL ARRAY WITH PATTERNED FILMS
2y 5m to grant Granted Mar 10, 2026
Patent 12560624
Automatic Analyzer
2y 5m to grant Granted Feb 24, 2026
Patent 12551890
MICROFLUIDIC SIPHONING ARRAY FOR NUCLEIC ACID QUANTIFICATION
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
78%
Grant Probability
98%
With Interview (+19.9%)
2y 10m
Median Time to Grant
High
PTA Risk
Based on 1354 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month